UK NICE Expands Access to Spinraza for SMA Type 3

UK NICE Expands Access to Spinraza for SMA Type 3

A decision from England’s National Institute for Health and Care Excellence (NICE) will make Spinraza (nusinersen) available to people with spinal muscular atrophy (SMA) type 3 who are unable to walk. In England, Spinraza is available through a managed access...